WO2011097527A3 - Immunoprotection de fractions thérapeutiques avec des régions fc améliorées - Google Patents
Immunoprotection de fractions thérapeutiques avec des régions fc améliorées Download PDFInfo
- Publication number
- WO2011097527A3 WO2011097527A3 PCT/US2011/023813 US2011023813W WO2011097527A3 WO 2011097527 A3 WO2011097527 A3 WO 2011097527A3 US 2011023813 W US2011023813 W US 2011023813W WO 2011097527 A3 WO2011097527 A3 WO 2011097527A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunoprotection
- enhanced
- regions
- therapeutic moieties
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
L'invention concerne des fractions thérapeutiques présentant une réponse immunogène réduite, utilisées en particulier à des fins thérapeutiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30151110P | 2010-02-04 | 2010-02-04 | |
US61/301,511 | 2010-02-04 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011097527A2 WO2011097527A2 (fr) | 2011-08-11 |
WO2011097527A9 WO2011097527A9 (fr) | 2011-12-08 |
WO2011097527A3 true WO2011097527A3 (fr) | 2012-01-26 |
Family
ID=44278062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/023813 WO2011097527A2 (fr) | 2010-02-04 | 2011-02-04 | Immunoprotection de fractions thérapeutiques avec des régions fc améliorées |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011097527A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
EP3258268A1 (fr) * | 2016-06-15 | 2017-12-20 | Protagen AG | Sequences de marqueurs pour la commande de therapie de patients atteints de polyarthrite rhumatoïde |
MA50948A (fr) | 2016-12-07 | 2020-10-14 | Agenus Inc | Anticorps et procédés d'utilisation de ceux-ci |
TW202328184A (zh) * | 2021-08-13 | 2023-07-16 | 大陸商舒泰神(北京)生物製藥股份有限公司 | 特異性識別fcrn的抗體及其用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
WO2004029207A2 (fr) * | 2002-09-27 | 2004-04-08 | Xencor Inc. | Variants fc optimises et methodes destinees a leur generation |
US20060269549A1 (en) * | 2004-01-08 | 2006-11-30 | Watkins Jeffry D | Tnf-alpha binding molecules |
WO2008008482A2 (fr) * | 2006-07-13 | 2008-01-17 | Genentech, Inc. | Polypeptides de liaison à br3 modifiés |
WO2008150494A1 (fr) * | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Procédés et compositions permettant l'inhibition de cellules d'expression du cd32b |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
WO2010033736A1 (fr) * | 2008-09-17 | 2010-03-25 | Xencor, Inc. | Nouvelles compositions et nouvelles méthodes de traitement d'affections médiées par les ige |
WO2011028952A1 (fr) * | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US459004A (en) | 1891-09-08 | Box for steaming cops | ||
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
CA1023287A (fr) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Procede de fixation d'une proteine sur un substrat |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (fr) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Traduction non-disponible |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
EP0272253A4 (fr) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | Procede pour ameliorer la stabilite des glycoproteines. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CZ282603B6 (cs) | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
EP0752248B1 (fr) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à differentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
CA2150262C (fr) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
WO1996040210A1 (fr) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Anticorps et fragments d'anticorps inhibant la croissance des tumeurs |
EP0915987A2 (fr) | 1997-04-21 | 1999-05-19 | Donlar Corporation | ACIDE POLY-$g(a)-L-ASPARTIQUE, ACIDE-POLY-$g(a)-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
ATE419354T1 (de) | 2000-02-25 | 2009-01-15 | Us Gov Health & Human Serv | Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US20040091485A1 (en) | 2000-05-19 | 2004-05-13 | Ellis John Robert Maxwell | Humanised antibodies to the epidermal growth factor receptor |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
MXPA00009407A (es) | 2000-09-26 | 2004-12-08 | Mexicano Inst Petrol | Procedimiento para la preparacion de un catalizador monometalico de tipo zeolitico para la obtencion de gasolinas de alto octando mediante reformacion de naftas. |
CA2785941C (fr) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Cellules produisant des compositions d'anticorps |
AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
DE60215819T2 (de) | 2001-08-03 | 2007-09-06 | Tyco Healthcare Group Lp, Norwalk | Marker zur verwendung mit einem gewebemarkierungsgerät |
WO2003073238A2 (fr) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Procede informatique de conception d'enzymes pour l'incorporation d'analogues d'acides amines dans des proteines |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
WO2005035727A2 (fr) | 2003-10-09 | 2005-04-21 | Ambrx, Inc. | Derives polymeres |
AU2005211385B2 (en) | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2011
- 2011-02-04 WO PCT/US2011/023813 patent/WO2011097527A2/fr active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
WO2004029207A2 (fr) * | 2002-09-27 | 2004-04-08 | Xencor Inc. | Variants fc optimises et methodes destinees a leur generation |
US20060269549A1 (en) * | 2004-01-08 | 2006-11-30 | Watkins Jeffry D | Tnf-alpha binding molecules |
WO2008008482A2 (fr) * | 2006-07-13 | 2008-01-17 | Genentech, Inc. | Polypeptides de liaison à br3 modifiés |
WO2008150494A1 (fr) * | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Procédés et compositions permettant l'inhibition de cellules d'expression du cd32b |
WO2010033736A1 (fr) * | 2008-09-17 | 2010-03-25 | Xencor, Inc. | Nouvelles compositions et nouvelles méthodes de traitement d'affections médiées par les ige |
WO2011028952A1 (fr) * | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes |
Non-Patent Citations (1)
Title |
---|
CHU SEUNG Y ET AL: "Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 45, no. 15, 1 September 2008 (2008-09-01), pages 3926 - 3933, XP002498116, ISSN: 0161-5890, [retrieved on 20080808], DOI: 10.1016/J.MOLIMM.2008.06.027 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011097527A2 (fr) | 2011-08-11 |
WO2011097527A9 (fr) | 2011-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012100224A3 (fr) | Préparation de réseaux métal- triazolate | |
EP3378850B8 (fr) | Procédés pour la préparation de (s)-l-(3-éthoxy-4-méthoxyphényl)-2- méthanesulfonyléthylamine | |
WO2011003902A3 (fr) | Matériau d'embolisation polymère visible multimodal | |
WO2012129341A3 (fr) | Détection d'une maladie chez les plantes | |
WO2012159051A3 (fr) | Graphène chimiquement modifié | |
EP2596711A4 (fr) | Dispositif de support | |
WO2013021279A3 (fr) | Anticorps fortement galactosylés | |
EP2563256A4 (fr) | Dispositif électrochirurgical et procédés | |
EP2529227A4 (fr) | Préparations immunogènes à base de cytomégalovirus | |
EP2662016A4 (fr) | Système d'endoscope capsulaire | |
MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
WO2011106692A9 (fr) | Procédés d'utilisation de l'acide (1s,3s)-3-amino-4-difluorométhylényl-1-cyclopentanoïque | |
DK2609931T3 (da) | Immunogen sammensætning | |
WO2012064743A3 (fr) | Procédés d'amélioration de la fonction cardiaque | |
WO2011097527A3 (fr) | Immunoprotection de fractions thérapeutiques avec des régions fc améliorées | |
CL2013000688A1 (es) | Procedimiento para obtener una composicion de igg a partir de una composicion de igg parcialmente purificada. | |
WO2011107866A3 (fr) | Dérivés silyliques de polysaccharides | |
EP2660232A4 (fr) | Nouvel alcool alicyclique | |
EP2660233A4 (fr) | Nouvel alcool alicyclique | |
FR2958500B1 (fr) | Preparation insecticide, insectifuge, ovicide, larvicide, nymphicide | |
IT1405996B1 (it) | Procedimento per la preparazione di 2,5-diaminotoluolo | |
EP2864328B8 (fr) | Composés pharmaceutiquement actifs | |
WO2012026907A3 (fr) | Préparations de cefpodoxime proxétil | |
ITTO20110857A1 (it) | Procedimento per la produzione di cicloesanonossina. | |
WO2011107921A3 (fr) | Composition de milnacipran à libération modifiée |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11704370 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11704370 Country of ref document: EP Kind code of ref document: A2 |